Roche and the American company Alnylam have announced positive results from a study with the drug zilebesiran. The blood pressure-lowering drug met the primary endpoint in the phase 2 trial called Kardia-2 after three months of treatment, Roche announced on Tuesday.
Zilebesiran demonstrated an encouraging safety and tolerability profile in adults with mild to moderate uncontrolled hypertension in combination with standard therapy. The results would support the potential of biannual dosing.
Results from the Kardia-2 trial are expected to be presented in April at the American College of Cardiology’s 2024 Annual Scientific Meeting. In addition, the Kardia-3 Phase II trial has already begun in adults with uncontrolled hypertension and high cardiovascular risk. (sda/awp)
Source: Blick
I am Ross William, a passionate and experienced news writer with more than four years of experience in the writing industry. I have been working as an author for 24 Instant News Reporters covering the Trending section. With a keen eye for detail, I am able to find stories that capture people’s interest and help them stay informed.
